Dynamic Kinetic Resolution for the Improved Manufacture of an Active Pharmaceutical Ingredient

A consortium comprising of Aesica Pharmaceuticals, Biocatalysts Ltd, CatScI Ltd and Charnwood Technical Consulting has been established as part of the Sustainable High-Value Chemical Manufacture through Industrial Biotechnology (IB) 2 competition from the TSB. The key goal of the project is to identify novel IB routes to an active pharmaceutical ingredient (API) that is currently manufactured through traditional chemical manufacturing techniques. The new technology has the potential to significantly reduce manufacturing costs whilst concomitantly allowing an increased output of the API with less manufacturing equipment. Additionally, this will have the added benefits of generating a more sustainable process as it will be more energy efficient and less reliant on hydrocarbon based technologies. A successful project will allow the consortium to compete with manufacture in low-cost economies and help ensure that production of this critical API continues in the United Kingdom.